Latest Lead News

Verity Resources reports robust Phase 1 drilling results at its Monument Gold Project, secures full ownership of Botswana copper-silver assets, and confirms significant rare earth mineralisation in Brazil, underpinning its growth strategy.

Terrain Minerals has raised $1.17 million through a placement to fund further drilling at its promising Smokebush Project, targeting high-grade gold and silver deposits.

Alpha HPA Limited reports significant progress on its HPA First Project Stage 2 construction and secures $30 million funding, while signing new letters of intent with leading semiconductor OEMs.

Tasman Resources has progressed its exploration efforts at Lake Torrens and Parkinson Dam projects, backed by a recent $850,000 capital raise and strategic board changes.

Aspire Mining Limited reports significant progress on its Ovoot Coking Coal Project, securing exclusive marketing rights and aligning infrastructure development with government-backed transport projects.

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.

SRJ Technologies has landed a US$269,000 contract to supply its BoltEx flange integrity solution to a leading FPSO operator offshore Guyana, marking a strategic foothold in a key offshore energy market.

BCAL Diagnostics has secured key partnerships and a $10 million convertible note facility to expand its cancer detection tests across Australia and New Zealand, marking steady commercial progress in Q3 2025.

Integral Diagnostics reports a robust FY25 with revenue climbing 33.7% to $628 million, driven by successful Capitol Health merger integration and strong growth in teleradiology. CEO Dr Ian Kadish announces retirement after eight transformative years.

Green360 Technologies has independently verified its Eco-Clay product as a high-performance, low-carbon cement substitute made from kaolin waste, poised to disrupt Australia’s $3.5 billion cement market.

Bubs Australia reported a 30% increase in net revenue to $25.6 million for Q1 FY26, driven by robust US sales and a return to profitability with positive EBITDA. Despite inventory challenges in other regions, the company maintains a solid cash position and anticipates FDA approval by year-end.

PainChek has secured FDA De Novo clearance for its Adult App, opening immediate access to a $175 million AUD US long-term care market and advancing its Infant App commercialization targeting a $15 billion AUD global opportunity.